...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS Research and Human Retroviruses >HIV Type 1 Antiretroviral Resistance Mutations in Subtypes B, C, and F in the City of Sao Paulo, Brazil
【24h】

HIV Type 1 Antiretroviral Resistance Mutations in Subtypes B, C, and F in the City of Sao Paulo, Brazil

机译：巴西圣保罗市B，C和F亚型的HIV 1型抗逆转录病毒耐药性突变

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In Brazil, where three distinct HIV-1 subtypes (B, F, and C) cocirculate, a significant portion of the HTV-infected population has been exposed to antiretroviral drugs. This study analyzes the antiretroviral resistance profiles of HTV-1-infected individuals failing antiretroviral therapy. Genotypic resistance profiles of 2474 patients presenting virologic failure to antiretroviral therapy in the city of Sao Paulo, Brazil, were generated and analyzed. Resistance mutations to protease inhibitors and nucleoside reverse transcriptase inhibitors were less common in subtype C viruses, whereas nonnucleoside reverse transcriptase inhibitor resistance mutations were less common in subtype F viruses. The thymidine analog mutation pathway known as pathway 1 was more prevalent in subtype B viruses than in subtype C viruses, whereas pathway 2 was more prevalent in subtype C viruses. Selected resistance mutations varied according to subtype for all three classes of antiretrovirals. We describe two distinct pathways of nonnucleoside reverse transcriptase inhibitor resistance (to nevirapine and efavirenz). Although cross-resistance to etravirine should occur more frequently among individuals failing nevirapine treatment, the prevalence of cross-resistance to etravirine, darunavir, and tipranavir was found to be low. We found that increases in the number of resistance mutations will be related to increases in the viral load. Special attention should be given to resistance profiles in non-B subtype viruses. The accumulation of knowledge regarding such profiles in the developing world is desirable.
机译：在巴西，三种不同的HIV-1亚型（B，F和C）共同传播，在HTV感染人群中，很大一部分已暴露于抗逆转录病毒药物。这项研究分析了抗逆转录病毒治疗失败的HTV-1感染者的抗逆转录病毒耐药性。生成并分析了巴西圣保罗市2474例抗逆转录病毒疗法病毒学失败的基因型耐药情况。对蛋白酶抑制剂和核苷逆转录酶抑制剂的抗性突变在C型亚型病毒中较不常见，而对非核苷逆转录酶抑制剂的抗性突变在F型亚型病毒中较不常见。在B型亚型病毒中，被称为途径1的胸苷类似物突变途径比在C型中更普遍，而在C型中则更普遍。对于所有三类抗逆转录病毒药物，选择的抗性突变根据亚型而变化。我们描述了非核苷逆转录酶抑制剂耐药性的两种不同途径（对奈韦拉平和依非韦伦）。尽管在接受奈韦拉平治疗失败的个体中，对依曲韦林的交叉耐药性发生频率更高，但发现对依曲韦林，地那那韦和替普那韦的交叉耐药率很低。我们发现，抗药性突变数量的增加将与病毒载量的增加有关。应特别注意非B亚型病毒的抗药性。希望在发展中国家积累有关此类概况的知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号